REGENXBIO Inc.
Company Stats
- Market Cap
- $497.1M
- as of Sep 30, 2026
- Shares Outstanding
- 66.0M
- Free Float
- 87.0%
Income Statement
- Revenue
- $170.4M
- Operating Income
- -$161.2M
- Net Income
- -$193.9M
- EBITDA
- -$145.6M
- Revenue Growth, 3Y
- 14.8%
- FCF Margin, 3Y Avg
- -179.3%
- FCF Margin, Worst Year
- -253.1%
Cash Flow
- Free Cash Flow
- -$126.4M
- FCF Yield
- -25.4%
- Owner FCF Yield
- -32.4%
Balance Sheet
- Cash & Equivalents
- $34.5M
Returns & Capital
- SBC, 3Y Avg
- $37.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $170.4M | -$126.4M | -74.1% |
| FY2024 | $83.3M | -$175.6M | -210.7% |
| FY2023 | $90.2M | -$228.4M | -253.1% |
| FY2022 | $112.7M | -$238.2M | -211.3% |
| FY2021 | $470.3M | $134.7M | 28.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 12, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back